Reduction in <scp>TIMP</scp>‐2 serum levels predicts remission of inflammatory bowel diseases

Carbone, Federico; Bodini, Giorgia; Brunacci, Matteo; Bonaventura, Aldo; Vecchiè, Alessandra; Liberale, Luca; Crespi, Mattia; Baldissarro, Isabella; Dallegri, Franco; Savarino, Vincenzo; Giannini, Edoardo G.

doi:10.1111/eci.13002

Cited by 16 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lower serum TIMP-4 levels have been found in IBD patients compared with healthy controls, whereas concentrations of serum TIMP-1 were higher in patients with CD and UC than healthy controls and also higher in active IBD compared with inactive disease and thus are promising markers for the diagnosis of IBD and for disease monitoring (77). Additionally, reduced levels of serum TIMP-2 at 14 weeks from baseline predicted long-term remission and good prognosis of patients who accepted anti-TNF therapy (78).…”

Section: Serum Biomarkers Indicating Intestinal Fibrosis Extracellulamentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

Section: Serum Biomarkers Indicating Intestinal Fibrosis Extracellulamentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Noteworthy, there is evidence that COVID‐19 may infect glandular cells of the digestive tract, including the rectum, determining inflammatory infiltrates characterised by the presence of interstitial oedema and lymphoplasmocytosis, although the actual association of this pathological evidence with gastrointestinal symptoms such as diarrhoea, which can be present in a proportion of patients with COVID‐19 infection, is still not clear 1,6,7 . Noteworthy, COVID‐19 infection is associated with a marked increase in levels of pro‐inflammatory cytokines such as interleukin‐1B and tumour necrosis factor‐alpha (TNF‐α), both implicated in the pathophysiology of inflammatory bowel disease (IBD), a disease characterised by relapse and remission phases, whose main clinical manifestations are fever, abdominal pain and diarrhoea, and where there is a complex interplay between inflammatory and remodelling processes involving several cytokines 3,8,9 …”

Section: Research Lettermentioning

confidence: 99%

Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management

Bodini

Demarzo

Casagrande

et al. 2020

Eur J Clin Investigation

Self Cite

View full text Add to dashboard Cite

“…Thus, by various measures, several other stool proteins outperform fecal calprotectin as biomarkers for IBD. In view of their biomarker potential and functional properties, these stool proteins merit further investigation, including hemoglobin, MMP-8 27 , MMP-9 28 , MMP-12, MPO 29 , lipocalin-2 30 , PGRP-S 31 , TIMP-1 27 , 32 , TIMP-2 27 , 33 , and Adiponectin 34 , 35 .…”

Section: Discussionmentioning

confidence: 99%

Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen

et al. 2021

View full text Add to dashboard Cite

In the search for improved stool biomarkers for inflammatory bowel disease (IBD), an aptamer-based screen of 1129 stool proteins was conducted using stool samples from an IBD cohort. Here we report that of the 20 proteins subsequently validated by ELISA, stool Ferritin, Fibrinogen, Haptoglobin, Hemoglobin, Lipocalin-2, MMP-12, MMP-9, Myeloperoxidase, PGRP-S, Properdin, Resistin, Serpin A4, and TIMP-1 are significantly elevated in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to controls. When tested in a longitudinal cohort of 50 UC patients at 4 time-points, fecal Fibrinogen, MMP-8, PGRP-S, and TIMP-2 show the strongest positive correlation with concurrent PUCAI and PGA scores and are superior to fecal calprotectin. Unlike fecal calprotectin, baseline stool Fibrinogen, MMP-12, PGRP-S, TIMP-1, and TIMP-2 can predict clinical remission at Week-4. Here we show that stool proteins identified using the comprehensive aptamer-based screen are superior to fecal calprotectin alone in disease monitoring and prediction in IBD.

show abstract

Reduction in TIMP‐2 serum levels predicts remission of inflammatory bowel diseases

Abstract: This study indicates TIMP-2 reduction during IBD treatment with monoclonal anti-TNF-α antibodies as a potential prognostic parameter of short and long term remission. To understand if TIMP-2 is an innocent biomarker or an active pathophysiological factor in IBD remains to be clarified.

Cited by 16 publications

References 24 publications

Serum Biomarkers for Inflammatory Bowel Disease

Serum Biomarkers for Inflammatory Bowel Disease

Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management

Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen

Contact Info

Product

Resources

About